Eftozanermin alfa

{
  "id": "MLC-T-ONC-013231",
  "term": "Eftozanermin alfa",
  "field": "Oncology and biomedicine",
  "definition": "A fusion protein composed of a tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor agonist consisting of six receptor binding domains (RBDs) of TRAIL fused to the Fc-domain of a human immunoglobulin G1 (IgG1) antibody, with potential pro-apoptotic and antineoplastic activities. Upon administration of eftozanermin alfa, this fusion protein binds to TRAIL-receptors, pro-apoptotic death receptors (DRs) TRAIL-R1 (death receptor 4; DR4) and TRAIL-R2 (death receptor 5; DR5), expressed on tumor cells, thereby inducing tumor cell apoptosis. ABBV-621 is designed to maximize receptor clustering for optimal efficacy. TRAIL, a member of the TNF superfamily of cytokines, plays a key role in the induction of apoptosis through TRAIL-mediated death receptor pathways.",
  "synonyms": [
    "hexavalent TRAIL receptor agonist ABBV-621",
    "HERA ligand ABBV-621",
    "TRAIL-Fc protein ABBV-621",
    "TRAIL-receptor Agonist Fusion Protein ABBV-621",
    "TRAIL receptor agonist ABBV-621"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/eftozanermin-alfa/"
}